Anita Turk, MD, details her biggest takeaways from the 2025 ASCO Annual Meeting in gastrointestinal cancers. Anita Turk, MD, medical oncologist at IU Health, discusses her biggest takeaways in the ...

Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

AEMD READ THE FULL AEMD RESEARCH REPORT Assessing if the Hemopurifier in conjunction with standard of care treatment can increase the population that can benefit from combined treatment Aethlon ...

Open Water Swim Brings 800+ Swimmers and Volunteers to Dive Into Long Island Sound to Support Cancer Research + 8 Additional ...

Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

Oral cancer, which includes malignancies affecting the lips, tongue, gums, cheeks, and floor of the mouth, represents a ...

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

Blue-chip dividend stocks are typically safe, and many are reasonably priced. Five may be incredible ideas for growth and income investors.